Show phenotypes

-
tree  Medical Subject Headings (MeSH) Human Phenotype Ontology (HPO)
Medical Subject Headings

Only the MeSH headings used in the annotation of phenotypes are displayed.
The numbers refer to the number of study phenotype methods annotated to that heading (at zero threshold) and all child headings where they exist.
The "OR" search operator is used when multiple headings are checked.







2020 MeSHlink created by U.S. National Library of Medicine


No data sets (in No Phenotypes) added to Browser
3,327 Phenotypes match your selection (showing 101-150)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
Phenotype tested in Study Phenotype ontology annotation Total p-values in Study StudyAdd data sets to Browser Related Study data
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) (Dominant model) (HGVPM3185)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) (Recessive model) (HGVPM3199)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) (Dominant model) (HGVPM3172)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) (Recessive model) (HGVPM3197)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Allelic model) (HGVPM3191)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Dominant model) (HGVPM3205)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) (Recessive model) (HGVPM3182)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Allelic model) (HGVPM3193)
  • Drug-Related Side Effects and Adverse Reactions
3 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Dominant model) (HGVPM3203)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) (Recessive model) (HGVPM3202)
  • Drug-Related Side Effects and Adverse Reactions
3 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Allelic model) (HGVPM3184)
  • Drug-Related Side Effects and Adverse Reactions
4 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Dominant model) (HGVPM3194)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) (Recessive model) (HGVPM3173)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) (HGVST1662)
Adverse response to chemotherapy in breast cancer (alopecia) (Allelic) (HGVPM3390)
  • Alopecia
  • Breast Neoplasms
  • Drug Therapy
1 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) (Allelic) (HGVPM3402)
  • Drug-Related Side Effects and Adverse Reactions
4 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) (Dominant) (HGVPM3398)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) (Recessive) (HGVPM3394)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) (Allelic) (HGVPM3399)
  • Drug-Related Side Effects and Adverse Reactions
4 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) (Dominant) (HGVPM3400)
  • Drug-Related Side Effects and Adverse Reactions
4 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) (Dominant) (HGVPM3395)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) (Recessive) (HGVPM3401)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) (Allelic) (HGVPM3392)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) (Dominant) (HGVPM3393)
  • Drug-Related Side Effects and Adverse Reactions
2 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) (Allelic) (HGVPM3396)
  • Drug-Related Side Effects and Adverse Reactions
1 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) (Dominant) (HGVPM3397)
  • Drug-Related Side Effects and Adverse Reactions
4 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Adverse response to chemotherapy in breast cancer (alopecia) (Recessive) (HGVPM3391)
  • Alopecia
  • Breast Neoplasms
  • Drug Therapy
2 GWAS of Adverse response to chemotherapy in breast cancer (alopecia) (HGVST1742)
Age at loss of ambulation in Duchenne muscular dystrophy (HGVPM7224)
  • Muscular Dystrophy, Duchenne
36 GWAS of Duchenne muscular dystrophy (HGVST3625)
age of onset of multiple sclerosis (HGVPM160)
  • Multiple Sclerosis
8 GWAS of multiple sclerosis (HGVST112)
Age of onset of Parkinson's disease (HGVPM814)
  • Parkinson Disease
5 GWAS of age of onset of Parkinson's disease (HGVST458)
Age spots (HGVPM3906)
  • Lentigo
3 GWAS of Skin-related traits (HGVST1907)
Age-related cataracts (HGVPM4216)
  • Cataract
3 GWAS of Cataracts (HGVST2091)
Age-related cataracts (age at onset) (HGVPM4217)
  • Cataract
3 GWAS of Cataracts (HGVST2091)
Age-related hearing impairment (HGVPM4063)
  • Hearing Loss
29 GWAS of Age-related hearing impairment (HGVST2005)
Age-related hearing impairment (HGVPM4661)
  • Hearing Loss
2 GWAS of Age-related hearing impairment (HGVST2360)
Age-related hearing impairment (SNP x SNP interaction) (HGVPM4062)
  • Hearing Loss
0 GWAS of Age-related hearing impairment (HGVST2005)
Age-related macular degeneration (HGVPM6)
  • Macular Degeneration
427,832 GWAS of age-related macular degeneration (HGVST4)
Age-related macular degeneration (HGVPM771)
  • Macular Degeneration
324,071 GWAS of age-related macular degeneration (HGVST435)
Age-related macular degeneration (HGVPM903)
  • Macular Degeneration
11 GWAS of age-related macular degeneration (HGVST501)
Age-related macular degeneration (HGVPM1093)
  • Macular Degeneration
4 GWAS of age-related macular degeneration (HGVST627)
Age-related macular degeneration (HGVPM1460)
  • Macular Degeneration
11 GWAS of age-related macular degeneration (HGVST860)
Age-related macular degeneration (HGVPM1546)
  • Macular Degeneration
2 GWAS of age-related macular degeneration (HGVST915)
Age-related macular degeneration (HGVPM2047)
  • Macular Degeneration
0 GWAS of Age-related macular degeneration (HGVST1230)
Age-related macular degeneration (HGVPM2165)
  • Macular Degeneration
6 GWAS of Age-related macular degeneration (HGVST1311)
Age-related macular degeneration (HGVPM2870)
  • Macular Degeneration
14 GWAS of Age-related macular degeneration (HGVST1565)
Age-related macular degeneration (HGVPM2896)
  • Macular Degeneration
0 GWAS of Age-related macular degeneration (HGVST1577)
Age-related macular degeneration (HGVPM3080)
  • Macular Degeneration
5 GWAS of Age-related macular degeneration (HGVST1623)
Age-related macular degeneration (HGVPM3261)
  • Macular Degeneration
17 GWAS of Age-related macular degeneration (HGVST1671)
Age-related macular degeneration (HGVPM3346)
  • Macular Degeneration
1 Common variant rs10033900 near complement factor I gene associated with age-related macular degeneration risk in Han Chinese population (HGVST1714)
Age-related macular degeneration (CNV) (HGVPM2163)
  • Macular Degeneration
6 GWAS of Age-related macular degeneration (CNV) (HGVST1310)
Age-related macular degeneration (EA) (HGVPM2871)
  • Macular Degeneration
15 GWAS of Age-related macular degeneration (HGVST1565)